MXPA00004530A - Compositions containing combinations of liquid polyol fatty acid polyesters and a liquid oil - Google Patents
Compositions containing combinations of liquid polyol fatty acid polyesters and a liquid oilInfo
- Publication number
- MXPA00004530A MXPA00004530A MXPA/A/2000/004530A MXPA00004530A MXPA00004530A MX PA00004530 A MXPA00004530 A MX PA00004530A MX PA00004530 A MXPA00004530 A MX PA00004530A MX PA00004530 A MXPA00004530 A MX PA00004530A
- Authority
- MX
- Mexico
- Prior art keywords
- fatty acid
- liquid
- further characterized
- oil
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 160
- 239000007788 liquid Substances 0.000 title claims abstract description 102
- -1 polyol fatty acid Chemical class 0.000 title claims abstract description 90
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 86
- 239000000194 fatty acid Substances 0.000 title claims abstract description 86
- 229920005862 polyol Polymers 0.000 title claims abstract description 66
- 229920000728 polyester Polymers 0.000 title claims abstract description 55
- 210000003491 Skin Anatomy 0.000 claims abstract description 37
- 150000004665 fatty acids Chemical group 0.000 claims abstract description 36
- 230000000699 topical Effects 0.000 claims abstract description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 28
- 150000003077 polyols Chemical group 0.000 claims abstract description 27
- 238000002844 melting Methods 0.000 claims abstract description 26
- 125000004432 carbon atoms Chemical group C* 0.000 claims abstract description 23
- 229920002401 polyacrylamide Polymers 0.000 claims abstract description 9
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940031674 LAURETH-7 Drugs 0.000 claims abstract description 8
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims abstract description 7
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methylpentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims abstract description 7
- XUGNVMKQXJXZCD-UHFFFAOYSA-N Isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940075495 isopropyl palmitate Drugs 0.000 claims abstract description 7
- 239000003921 oil Substances 0.000 claims description 49
- 235000019198 oils Nutrition 0.000 claims description 48
- 239000005720 sucrose Substances 0.000 claims description 42
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims description 39
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 38
- 229960004793 Sucrose Drugs 0.000 claims description 37
- 239000000516 sunscreening agent Substances 0.000 claims description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 229960001031 Glucose Drugs 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 239000006210 lotion Substances 0.000 claims description 11
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 10
- 230000000475 sunscreen Effects 0.000 claims description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 150000002430 hydrocarbons Chemical class 0.000 claims description 9
- 239000000600 sorbitol Substances 0.000 claims description 9
- 235000010356 sorbitol Nutrition 0.000 claims description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 9
- 239000002480 mineral oil Substances 0.000 claims description 8
- 235000010446 mineral oil Nutrition 0.000 claims description 8
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- 239000004909 Moisturizer Substances 0.000 claims description 6
- 230000001333 moisturizer Effects 0.000 claims description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 Xylitol Drugs 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- 229940009714 Erythritol Drugs 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 230000003750 conditioning Effects 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- 230000001815 facial Effects 0.000 claims description 4
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 206010000496 Acne Diseases 0.000 claims description 3
- 235000001727 glucose Nutrition 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 239000002884 skin cream Substances 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 230000001012 protector Effects 0.000 claims description 2
- 230000001172 regenerating Effects 0.000 claims description 2
- 238000005187 foaming Methods 0.000 claims 1
- 239000007934 lip balm Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 abstract description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 19
- 239000004615 ingredient Substances 0.000 description 18
- 150000002148 esters Chemical class 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 13
- 239000003549 soybean oil Substances 0.000 description 13
- 235000012424 soybean oil Nutrition 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 239000003974 emollient agent Substances 0.000 description 11
- 239000002537 cosmetic Substances 0.000 description 10
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 9
- 229940079593 drugs Drugs 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- 229920001888 polyacrylic acid Polymers 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000004264 Petrolatum Substances 0.000 description 5
- 229940066842 Petrolatum Drugs 0.000 description 5
- 229960003487 Xylose Drugs 0.000 description 5
- 125000005250 alkyl acrylate group Chemical group 0.000 description 5
- 230000000845 anti-microbial Effects 0.000 description 5
- 239000008406 cosmetic ingredient Substances 0.000 description 5
- 235000020778 linoleic acid Nutrition 0.000 description 5
- 235000021313 oleic acid Nutrition 0.000 description 5
- 235000019271 petrolatum Nutrition 0.000 description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 3
- WXZMFSXDPGVJKK-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 3
- UQEAIHBTYFGYIE-UHFFFAOYSA-N Hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 3
- 229960000448 Lactic acid Drugs 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 150000001253 acrylic acids Chemical class 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 230000003255 anti-acne Effects 0.000 description 3
- 230000000111 anti-oxidant Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 150000001479 arabinose derivatives Chemical class 0.000 description 3
- 239000003212 astringent agent Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 125000005313 fatty acid group Chemical group 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229960003500 triclosan Drugs 0.000 description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
- FKMHSNTVILORFA-UHFFFAOYSA-N 2-[2-(2-dodecoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCO FKMHSNTVILORFA-UHFFFAOYSA-N 0.000 description 2
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- 229960001631 Carbomer Drugs 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N Dodecanol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N Erucic acid Chemical class CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 2
- YTBSYETUWUMLBZ-IUYQGCFVSA-N Erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 2
- 206010056474 Erythrosis Diseases 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N Eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 240000007842 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 229940057905 Laureth-3 Drugs 0.000 description 2
- 210000000088 Lip Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- MHIGBKBJSQVXNH-IWVLMIASSA-N Metacycline Chemical compound C=C([C@H]1[C@@H]2O)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O MHIGBKBJSQVXNH-IWVLMIASSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl methoxycinnamate Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- 229960000625 Oxytetracycline Drugs 0.000 description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 2
- 239000004100 Oxytetracycline Substances 0.000 description 2
- 229940100460 PEG-100 Stearate Drugs 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N Pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- 229960004448 Pentamidine Drugs 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N Phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 229960005323 Phenoxyethanol Drugs 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N Piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229960002180 Tetracycline Drugs 0.000 description 2
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 2
- 229960001727 Tretinoin Drugs 0.000 description 2
- 229940046282 Zinc Drugs 0.000 description 2
- 229940091251 Zinc Supplements Drugs 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000003444 anaesthetic Effects 0.000 description 2
- 230000000202 analgesic Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 229960003328 benzoyl peroxide Drugs 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 229960004275 glycolic acid Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000011874 heated mixture Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- BJHIKXHVCXFQLS-PYWDMBMJSA-N keto-D-sorbose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PYWDMBMJSA-N 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960003494 metacycline Drugs 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 235000019366 oxytetracycline Nutrition 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical class OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229950001046 piroctone Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229960001755 resorcinol Drugs 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960005349 sulfur Drugs 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000010698 whale oil Substances 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N (1S,3R,4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,25R,27R,29R,32R,33R,35S,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- AGFWIZQEWFGATK-UNZHCMSXSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](NC)[C@@](C)(O)CO1)O)NCC)[C@H]1OC(CN)=CC[C@H]1N.O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](NC)[C@@](C)(O)CO1)O)NCC)[C@H]1OC(CN)=CC[C@H]1N AGFWIZQEWFGATK-UNZHCMSXSA-N 0.000 description 1
- FIWSRSRCWYARAJ-SQOFCNSWSA-N (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol;(Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FIWSRSRCWYARAJ-SQOFCNSWSA-N 0.000 description 1
- AUODDLQVRAJAJM-XJQDNNTCSA-N (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 AUODDLQVRAJAJM-XJQDNNTCSA-N 0.000 description 1
- OIQXFRANQVWXJF-QBFSEMIESA-N (2Z)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound CC1(C)C2CCC1(C)C(=O)\C2=C/C1=CC=CC=C1 OIQXFRANQVWXJF-QBFSEMIESA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3S)-3,6-diamino-N-[[(2S,5S,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-CVHRZJFOSA-N (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-CVHRZJFOSA-N 0.000 description 1
- YCIHPQHVWDULOY-FMZCEJRJSA-N (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O YCIHPQHVWDULOY-FMZCEJRJSA-N 0.000 description 1
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 1
- QYAPHLRPFNSDNH-LYNLVHCPSA-N (4S,4aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)C3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-LYNLVHCPSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- OIJAYOZHXTXUBD-TXDFQOQUSA-N (Z)-octadec-9-enoic acid;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCC\C=C/CCCCCCCC(O)=O OIJAYOZHXTXUBD-TXDFQOQUSA-N 0.000 description 1
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N 1-Tetradecanol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 description 1
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 1
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-Methyl-2,4-pentanediol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N 2-[6-[[amino-[[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;hydron;dichloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- ZQBJRVYLUFBBEQ-UHFFFAOYSA-N 2-[diamino(3-formamidopropyl)azaniumyl]acetate Chemical compound [O-]C(=O)C[N+](N)(N)CCCNC=O ZQBJRVYLUFBBEQ-UHFFFAOYSA-N 0.000 description 1
- ICFRVXBXPFMEST-UHFFFAOYSA-N 2-butyl-1,3-diphenylpropane-1,3-dione Chemical group C=1C=CC=CC=1C(=O)C(CCCC)C(=O)C1=CC=CC=C1 ICFRVXBXPFMEST-UHFFFAOYSA-N 0.000 description 1
- NEQXUPRFDXNNTA-UHFFFAOYSA-N 2-hydroxyethylazanium;2-hydroxypropanoate Chemical compound [NH3+]CCO.CC(O)C([O-])=O NEQXUPRFDXNNTA-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N 2-phenyl-3H-benzimidazole-5-sulfonic acid Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- IJTPQQVCKPZIMV-UHFFFAOYSA-N 4-(3-chloro-4-cyclohexylphenyl)-4-oxobutanoic acid Chemical compound ClC1=CC(C(=O)CCC(=O)O)=CC=C1C1CCCCC1 IJTPQQVCKPZIMV-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- HEOCBCNFKCOKBX-SDNWHVSQSA-N 4-Methylbenzylidene camphor Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)C2(C)CCC\1C2(C)C HEOCBCNFKCOKBX-SDNWHVSQSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UMZBRFQRSA-N 4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CCC1(C)C1C2C2CCC(C(CCC(O)=O)C)C2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UMZBRFQRSA-N 0.000 description 1
- BDQHDFBEAFMWII-UHFFFAOYSA-N 6-hydroxyhexanal;hydrochloride Chemical compound Cl.OCCCCCC=O BDQHDFBEAFMWII-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 1
- 229940063953 AMMONIUM LAURYL SULFATE Drugs 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 229940022659 Acetaminophen Drugs 0.000 description 1
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Alimemazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N Alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960001656 Amikacin Sulfate Drugs 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N Ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 241000557821 Azadirachta Species 0.000 description 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Azelaic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 1
- 235000019490 Beech nut oil Nutrition 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- 229940093761 Bile Salts Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000006463 Brassica alba Nutrition 0.000 description 1
- 244000140786 Brassica hirta Species 0.000 description 1
- 235000011371 Brassica hirta Nutrition 0.000 description 1
- 229950005608 Bucloxic acid Drugs 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N Bupivacaine Chemical class CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- GGQJXCQBBONZFX-IWVLMIASSA-N CHEMBL1237124 Chemical compound C=C([C@H]1[C@@H]2O)C3=C(Cl)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O GGQJXCQBBONZFX-IWVLMIASSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical class C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 229960000846 Camphor Drugs 0.000 description 1
- JNIIDKODPGHQSS-DHDCSXOGSA-N Capreomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)C(CNC(=O)CC(N)CCCN)NC(=O)C(CO)NC(=O)C(N)CNC(=O)C1C1NC(N)=NCC1 JNIIDKODPGHQSS-DHDCSXOGSA-N 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 229960002968 Capreomycin Sulfate Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N Carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229960003260 Chlorhexidine Drugs 0.000 description 1
- 229960004504 Chlorhexidine Hydrochloride Drugs 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960004475 Chlortetracycline Drugs 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 229960003185 Chlortetracycline Hydrochloride Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 229960001200 Clindamycin Hydrochloride Drugs 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229940031766 DIETHANOLAMINE CETYL PHOSPHATE Drugs 0.000 description 1
- 229960004082 DOXYCYCLINE HYDROCHLORIDE Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 229940009976 Deoxycholate Drugs 0.000 description 1
- 229940120503 Dihydroxyacetone Drugs 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N Dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- VJHINFRRDQUWOJ-UHFFFAOYSA-N Dioctyl sebacate Chemical compound CCCCC(CC)COC(=O)CCCCCCCCC(=O)OCC(CC)CCCC VJHINFRRDQUWOJ-UHFFFAOYSA-N 0.000 description 1
- 229940101029 Dipotassium Glycyrrhizinate Drugs 0.000 description 1
- 229920004511 Dow Corning® 200 Fluid Polymers 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229960000385 Dyclonine Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N Dyclonine Chemical class C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229960003203 Erythromycin Estolate Drugs 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N Ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- 229960000285 Ethambutol Drugs 0.000 description 1
- 229960001618 Ethambutol Hydrochloride Drugs 0.000 description 1
- 229960003976 Etidocaine Drugs 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical class CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 229940044949 Eucalyptus oil Drugs 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 229960002217 Eugenol Drugs 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N Fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229950001284 Fluprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N Glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 241000558306 Gynocardia odorata Species 0.000 description 1
- ROAIXOJGRFKICW-UHFFFAOYSA-N Haiprex Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CNC(=O)C1=CC=CC=C1 ROAIXOJGRFKICW-UHFFFAOYSA-N 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- DCAYPVUWAIABOU-UHFFFAOYSA-N Hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N Hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- UXNFIJPHRQEWRQ-UHFFFAOYSA-N Hexamethylenetetramine mandelate salt Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)C(O)C1=CC=CC=C1 UXNFIJPHRQEWRQ-UHFFFAOYSA-N 0.000 description 1
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical class C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N Homosalate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- 229960004881 Homosalate Drugs 0.000 description 1
- 229940089456 ISOPROPYL STEARATE Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- RJMIEHBSYVWVIN-UHFFFAOYSA-N Indoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-UHFFFAOYSA-N 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960002064 Kanamycin Sulfate Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- OYHQOLUKZRVURQ-UHFFFAOYSA-N Linoleic acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 1
- 241000252067 Megalops atlanticus Species 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- 229940051860 Methacycline hydrochloride Drugs 0.000 description 1
- 229960004011 Methenamine Drugs 0.000 description 1
- 229960000282 Metronidazole Drugs 0.000 description 1
- 229960002395 Metronidazole Hydrochloride Drugs 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960002421 Minocycline Hydrochloride Drugs 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- WVMBPWMAQDVZCM-UHFFFAOYSA-N N-methylanthranilic acid Chemical compound CNC1=CC=CC=C1C(O)=O WVMBPWMAQDVZCM-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N Neomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 229940053050 Neomycin Sulfate Drugs 0.000 description 1
- 229960000808 Netilmicin Drugs 0.000 description 1
- 229960004832 Netilmicin Sulfate Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N Norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 Norfloxacin Drugs 0.000 description 1
- OVVINEZSSVQLTB-NRQGAZJASA-N OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O OVVINEZSSVQLTB-NRQGAZJASA-N 0.000 description 1
- SKLXVOYUKZEQHP-FHUUETBYSA-N OC[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O SKLXVOYUKZEQHP-FHUUETBYSA-N 0.000 description 1
- 229960003921 Octisalate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N Octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N Oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229940082415 PISTACHIO OIL Drugs 0.000 description 1
- 229940115476 PPG-1 TRIDECETH-6 Drugs 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 229960005065 Paromomycin Sulfate Drugs 0.000 description 1
- 241000283222 Physeter catodon Species 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N Pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 235000019497 Pistachio oil Nutrition 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940068977 Polysorbate 20 Drugs 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N Pramocaine Chemical class C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 229940100459 STEARETH-20 Drugs 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229950011392 Sorbitan stearate Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 229960002385 Streptomycin Sulfate Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 229960002372 Tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical class CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960000707 Tobramycin Drugs 0.000 description 1
- 229960004477 Tobramycin Sulfate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N Tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229940035740 Trimeprazine Drugs 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229940045997 Vitamin A Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 229940118846 Witch Hazel Drugs 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical class CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- UJNOLBSYLSYIBM-NOOOWODRSA-N [(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl] (2S)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@H](C)O UJNOLBSYLSYIBM-NOOOWODRSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- OCRUMFQGIMSFJR-FSAWCSQFSA-N [(2S,3S,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-[(Z)-octadec-9-enoyl]oxy-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl (Z)-octadec-9-enoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC OCRUMFQGIMSFJR-FSAWCSQFSA-N 0.000 description 1
- ZZXIXQRNGZFIQT-JSJITEFISA-N [(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl (Z)-octadec-9-enoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O ZZXIXQRNGZFIQT-JSJITEFISA-N 0.000 description 1
- HVUMOYIDDBPOLL-IIZJTUPISA-N [2-[(2R,3S,4R)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@@H](O)[C@@H]1O HVUMOYIDDBPOLL-IIZJTUPISA-N 0.000 description 1
- SCMSRHIBVBIECI-UHFFFAOYSA-N [2-hydroxy-4-(2-hydroxyethoxy)phenyl]-phenylmethanone Chemical compound OC1=CC(OCCO)=CC=C1C(=O)C1=CC=CC=C1 SCMSRHIBVBIECI-UHFFFAOYSA-N 0.000 description 1
- YPKOTWSAVCIFAM-UHFFFAOYSA-N [Na].CCC Chemical compound [Na].CCC YPKOTWSAVCIFAM-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- DHFCLYNGVLPKPK-UHFFFAOYSA-N acetamide;2-aminoethanol Chemical compound CC(N)=O.NCCO DHFCLYNGVLPKPK-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- FXKSEJFHKVNEFI-GCZBSULCSA-N amikacin disulfate Chemical compound [H+].[H+].[H+].[H+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O FXKSEJFHKVNEFI-GCZBSULCSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging Effects 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000842 anti-protozoal Effects 0.000 description 1
- 230000001153 anti-wrinkle Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drugs Oxicams Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic products Propionic acid derivatives Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- 229930000006 bisabolols Natural products 0.000 description 1
- 239000001919 brassica nigra l. koch seed oil Substances 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229930007890 camphor Natural products 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Chemical class O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical class O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- CLLKUSRBGZGQSF-UHFFFAOYSA-N dodecyl hydrogen sulfate;ethane-1,2-diol;2-(2-hydroxyethylamino)ethanol Chemical compound OCCO.OCCNCCO.CCCCCCCCCCCCOS(O)(=O)=O CLLKUSRBGZGQSF-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 1
- 229950001028 erythromycin propionate Drugs 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229930003935 flavonoids Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical class OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 230000003370 grooming Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- GKKMCECQQIKAHA-UHFFFAOYSA-N hexadecyl dihydrogen phosphate;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.CCCCCCCCCCCCCCCCOP(O)(O)=O GKKMCECQQIKAHA-UHFFFAOYSA-N 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-L hexadecyl phosphate Chemical compound CCCCCCCCCCCCCCCCOP([O-])([O-])=O ZUVCYFMOHFTGDM-UHFFFAOYSA-L 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- 229960005388 hexylcaine Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 229910000460 iron oxide Inorganic materials 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 230000001530 keratinolytic Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010699 lard oil Substances 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229950004594 levomenol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 229960000826 meclocycline Drugs 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical class CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960003900 methenamine hippurate Drugs 0.000 description 1
- 229960002786 methenamine mandelate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical compound Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- GLMUAFMGXXHGLU-VQAITOIOSA-N minocycline hydrochloride Chemical compound [H+].[Cl-].C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O GLMUAFMGXXHGLU-VQAITOIOSA-N 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000003020 moisturizing Effects 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- FCJSHPDYVMKCHI-UHFFFAOYSA-N phenyl benzoate Chemical class C=1C=CC=CC=1C(=O)OC1=CC=CC=C1 FCJSHPDYVMKCHI-UHFFFAOYSA-N 0.000 description 1
- 230000003711 photoprotective Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000010665 pine oil Substances 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- 239000010471 pistachio oil Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002553 poly(2-methacrylolyloxyethyltrimethylammonium chloride) polymer Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2(1H)-one Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000037335 skin penetration Effects 0.000 description 1
- 231100000051 skin sensitiser Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 230000002087 whitening Effects 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
Abstract
Disclosed are compositions suitable for topical application to human hair or skin, which comprise (a) from about 0.1%to about 99.9%by weight of a liquid polyol fatty acid polyester having a melting point of from about -30°C to about 30°C, wherein the liquid polyol fatty acid polyester has a polyol moiety and at least 1 fatty acid moiety, the polyol moiety having at least 4 free hydroxyl groups wherein at least 60%of these free hydroxyl groups are esterified with one or more fatty acid moieties having from about 8 to about 22 carbon atoms;and (b) from about 0.1%to about 99.9%by weight of a liquid oil having a melting point of from about -30°C to less than about 30°C, wherein the liquid oil is subtantially free of liquid polyol fattyacid polyesters, isohexadecane, isopropyl palmitate, or blends of C13-C14 isoparrafins and polyacrylamide and laureth-7. The composition preferably further comprises a topical carrier for the liquid polyol fatty acid polyester and liquid oil combination. The composition provides effective emolliency and aesthetic benefits.
Description
COMPOSITIONS CONTAINING COMBINATIONS OF LIQUID POLYOLIC POLYESTERS AND LIQUIDS AND OILS
LIQUIDS
FIELD OF THE INVENTION
The present invention relates to compositions suitable for topical application in human hair or skin including a select combination of liquid polyol fatty acid polyesters with a melting point of between -30 ° C to 30 ° C, and a select liquid oil. with a melting point between -30 ° C and less than 30 ° C.
BACKGROUND OF THE INVENTION
Topical emollient-containing compositions have been used for many years for the treatment of human hair or skin. For example, occlusive hydrocarbons, such as petrolatum or petrolatum, have been used as topical emollients to provide a protective layer on human skin that helps prevent the loss of water caused by interaction with the environment. Petrolatum has also been used in hair care products such as conditioners and other cleaning aids.
However, the most effective and widely used compositions containing occlusive emollients have adverse characteristics as regards their aesthetic qualities, since they are greasy and sticky. In addition, some of the occlusive emollients that are used to provide a protective layer on the skin clog pores thereof and impede the flow of oxygen. This obstruction of the surface of the skin or blockage of the passage or circulation of air and moisture limits the use of this type of heavy and occlusive emollient materials. Additionally the European patent no. 458,600 B1, issued March 2, 1994, describes occlusive skin care compositions containing a polyol fatty acid polyester with at least 4 free hydroxyl groups, at least 60% of which are esterified with one or more acids fatty acids that have between 8 and 22 carbon atoms that can form a film or occlusive layer on the skin after they are applied topically on it. The US patent no. 5,160,738, issued to Macaulay et al., On November 3, 1992, discloses other occlusive compositions containing a mixture of two or more polyol fatty acid polyesters with the appearance and physical characteristics of the petrolatum. However, these compositions have the disadvantage of being heavy, clogging the pores of the skin and preventing the flow of oxygen. Therefore, there is a need to find materials that are emollient and that also have acceptable aesthetic qualities, without being heavy or occlusive.
It has now been found that it is possible to formulate compositions containing non-occlusive emollients without being heavy, sticky or greasy. These compositions contain a select combination of liquid polyol fatty acid polyesters with a melting point of about -30 ° C to about 30 ° C, and a liquid oil with a melting point of between -30 ° C and less than 30 ° C, characterized in that the liquid oil is substantially free of liquid polyol fatty acid polyesters, isohexadecane, isopropyl palmitate or mixtures of Ci3-C isoparaffins? and polyacrylamide and laureth-7. These compositions can be incorporated into various products to provide both emollient and aesthetic benefits. It is therefore the object of this invention to provide a composition having acceptable and effective emollient and aesthetic qualities, and containing a non-occlusive emollient used in combination with a select liquid oil. It is also the object of this invention to provide topical compositions containing polyol fatty acid polyesters which are not heavy, sticky and greasy, and which are effective in the treatment of human hair or skin.
BRIEF DESCRIPTION OF THE INVENTION
The present invention relates to a composition suitable for topical application on human hair or skin, which includes (a) between 0.1% and 99.9% by weight of a liquid polyol fatty acid polyester with a melting point of between -30 ° C and about 30 ° C, characterized in that the polyester of liquid polyol fatty acid has a polyol moiety and at least one fatty acid moiety, and the polyol moiety has at least 4 free hydroxyl groups characterized in that at least 60% of these free hydroxyl groups are esterified with one or more fatty acid moieties containing between 8 and 22 carbon atoms; and (b) between 0.1% and 99.9% by weight of a liquid oil with a melting point between -30 ° C and less than 30 ° C, characterized in that this liquid oil is substantially free of liquid polyol fatty acid polyesters, isohexadecane, isopropyl palmitate or mixtures of C13-C14 isoparaffins and polyacrylamide and laureth-7. Preferably, the composition further includes a topical vehicle for the combination of polyester of liquid polyol fatty acid and liquid oil. All percentages and ratios used herein are by weight and all measurements are made at 25 ° C, unless otherwise indicated. The invention of the present may include, consist of, or essentially include the fundamental ingredients, as well as the ingredients and optional components described herein.
DETAILED DESCRIPTION OF THE INVENTION
The term "topical composition", as used herein, means a composition suitable for topical application on the hair or skin of a human being. The term is used to cover a whole series of cosmetic compositions, for personal care and beauty articles. Some of these topical compositions, but not limitingly, are lotions, creams, body lotions and hand lotions, skin conditioning lotions and creams, skin protection compositions, sunscreens, skin creams, compositions against acne, skin regenerating products, cleansing lotions that do not create foam, moisturizers, facial moisturizers, makeup, foundation for makeup, lipsticks, lip protectors, skin cleansers, hand cleaners, face and body, products for bathing, shampoos and the like. The term "topical carrier", as used herein, is well known to those skilled in the art and means one or more compatible solid or liquid fillers, diluents or carriers suitable for administration to humans. The term "compatible", as used herein, means that the components of the topical vehicle can be mixed with the components of the present invention, as well as with each other, such that there is no interaction that could significantly reduce the effectiveness or aesthetic qualities of the cosmetic composition under ordinary conditions of use. The topical vehicle must be a pharmaceutically acceptable vehicle. The term "pharmaceutically acceptable", as used herein, means that the topical carrier must be of sufficient purity and must be suitable for use upon contact with human hair or skin without toxicity, incompatibility, instability, allergic response and the like. The term "liquid", as used herein, refers to materials that are spillable fluids under ambient conditions of a pressure atmosphere, with about 50% relative humidity and about 20 ° C to about 25 °. C, unless otherwise specified. The term "selected liquid oils", as used herein, refers to liquid oil materials that have a melting point of less than about 30 ° C and that are substantially free of liquid polyol fatty acid polyesters, isohexadecane , isopropyl palmitate, or mixtures of C13-C14 isoparaffins and polyacrylamide and laureth-7.
In this context, the term "substantially free" means that the compositions preferably contain less than an effective amount of these materials when used in combination with the liquid polyol fatty acid polyester to provide emollient and aesthetic benefits.
Generally, the compositions contain less than 1%, preferably less than 0.5%, most preferably less than 0.25%, most preferably still less than 0.1%, and most preferably 0% by weight of these materials of the composition. The melting point of the liquid polyol fatty acid polyesters can be determined using conventional techniques. These techniques are well known to experts, and include thermometric and calorimetric methodologies. A particularly preferred technique for determining the melting point is that described in U.S. Pat. do not. 5,306,514, issued Letton et al., April 26, 1994, which is incorporated herein by reference. This technique commonly uses the measurement of melting points by Differential Scanning Calorimetry (DSC), characterized in that a scanning temperature of 5 ° C / min is used to measure the melting point. The melting point is the temperature at which the baseline linear crosses, this is the specific heat line, and the line tangent to the trailing edge of the endothermic peak.
Liquid polyol fatty acid polyester The composition of the present invention includes a non-occlusive liquid polyol fatty acid polyester at concentrations between 0.1% and 99.9%, preferably between 0.5% and 75%, most preferably between 1% and 50%, very preferably still between 2% and 25% by weight of the composition. These liquid polyol fatty acid polyesters have melting points below about 30 ° C, and are derived from any aliphatic or aromatic polyol having at least 4 free hydroxyl groups, of which at least 60% of these are then esterified with one or more fatty acids having between 8 and about 22 carbon atoms. Fatty acids can also be described as carboxylic acids, because the terms fatty acid and carboxylic acid are used interchangeably by those skilled in the art.
Among the liquid polyol polyesters used in this invention are certain polyols, especially sugars or sugar alcohols, esterified with one or more fatty acid groups. Accordingly, the polyol starting material must have at least 4 esterifiable hydroxyl groups. Among the preferred polyols are the sugars, including monosaccharides and disaccharides and sugar alcohols. Among the monosaccharides containing 4 hydroxyl groups are xylose and arabinose, and sugar alcohol derived from xylose, which has 5 hydroxyl groups, that is, xylitol. The monosaccharide erythrose is not suitable in the practice of this invention since it contains only three hydroxyl groups, but the sugar alcohol derived from erythrose, these is erythritol, contains 4 hydroxyl groups and can therefore be used. Among the monosaccharides containing five convenient hydroxyl groups are galactose, fructose and sorbose. Sugar alcohols containing six hydroxyl groups derived from the products of the hydrolysis of sucrose, as well as glucose and sorbose, for example sorbitol, are also convenient. Among the disaccharide polyols that can be used are maltose, lactose and sucrose, which contain eight hydroxyl groups. The polyols used in the liquid polyol esters of the present invention have between 4 and about 12, preferably between 4 and 11, and most preferably between 4 and 8 hydroxyl groups. The preferred polyols for preparing the polyesters that are used in the present invention are selected from a group consisting of erythritol, xylitol, sorbitol, glucose and sucrose. Sucrose is especially preferred. The preferred polyol starting material with at least four hydroxyl groups must be esterified in at least 60% of the hydroxyl groups with a fatty acid containing about 8 to 22 carbon atoms, preferably between 8 and 18 carbon atoms . Among these fatty acids are caprylic, capric, lauric, myristic, myristoleic, palmitic, palmitoleic, stearic, oleic, resinoléic, linoleic, linolenic, elephantic, ariquídic, arachidonic, behenic, and erucic acids. Fatty acids can be derived from natural or synthetic fatty acids. They can be saturated or unsaturated, including positional and geometric isomers. However, to obtain liquid polyesters of the type used herein, at least half of the fatty acid incorporated into the polyester molecule must be unsaturated. Especially preferred are oleic and linoleic acids, and mixtures thereof. The liquid polyol fatty acid polyesters useful in this invention should contain one or more fatty acid ester groups. It is not necessary that all hydroxyl groups of the polyol be esterified with fatty acids, but it is preferable that at least 60% of the hydroxyl groups be esterified with fatty acid ester groups. Most preferably, substantially all the hydroxyl groups of the polyol are esterified with fatty acids, that is, the polyol portion is substantially completely esterified. The fatty acids esterified in the polyol molecule can be itself or mixtures, but as indicated above, there must be a substantial amount of the unsaturated acid ester groups to obtain liquid characteristics. To illustrate the above, sucrose fatty acid ester would be convenient for use herein, but it is not preferred since it has more than two non-esterified hydroxyl groups. Likewise, the tetraacid ester of sucrose would be convenient, but it is not preferred since it has more than two unesterified hydroxyl groups. Among the highly preferred compounds in which all hydroxyl groups are esterified with fatty acids are the suctasubstated fatty acid esters of liquid sucrose. Among the specific liquid polyol fatty acid polyesters containing one or more fatty acid ester groups suitable for use in the present invention are, but are not limited to: glucose oleate, glucose ester, fatty acid, fatty acid soybean (unsaturated), mixed soybean oil fatty acid maleate ester, oleic acid galactose ester, linoleic acid arabinose ester, xylose linoleate, sorbitol oleate, sucrose oleate, glucose dioleate, glucose diester of soybean oil fatty acids (unsaturated), mixed soybean oil fatty acid diesters, oleic acid galactose diesters, linoleic acid arabinose diesters, xylose dilinoleate, sorbitol dioleate, sucrose dioleate, trioleate glucose, glucose triesters of soybean oil fatty acids (unsaturated), mixed soybean oil fatty acid trésteres , triesters of galactose of oleic acid, triesters of arabinose of linoleic acid, trilinoleate of xylose, trioleate of sorbitol, trioleate of sucrose, tetraesters of glucose of fatty acids of soybean oil (unsaturated) tetraesters of mañosa of fatty acids of soybean oil mixtures, tetraesters of galactose of oleic acid, tetraesters of arabinose of linoleic acid, tetralinoleate of xylose, tetraoleate of sorbitol, pentaoleate of galactose, hexaesters of sorbitol of fatty acids of unsaturated soybean oil, xylitol pentaoleate, sucrose tretaoleate, pentaoleate sucrose, sucrose hexaoleate, sucrose heptaoleate, sucrose octaoleate and mixtures thereof. Liquid polyol esters selected from a group consisting of sucrose pentaoleate, sucrose hexaoleate, sucrose heptaoleate, sucrose octaoleate and mixtures thereof are preferred. Most preferably sucrose hexaoleate, sucrose heptaoleate, sucrose octaoleate and mixtures thereof. The preferred liquid polyol fatty acid polyesters of the present invention have melting points of between -30 ° C and about 30 ° C, preferably -30 ° C and 27.5 ° C, and most preferably between -30 ° C and 25 ° C. ° C. The melting points are measured using conventional techniques. The polyol fatty acid polyesters suitable for use herein can be made by various methods well known in the art. Among these methods is: the transesterification of polio! with fatty acid esters of methyl, ethyl or glycerol using a variety of catalysts; the acylation of the polyol with a fatty acid chloride; the acylation of the polyol with a fatty acid anhydride; and the acylation of the polyol with a fatty acid, by itself. See the patent of E.U.A. No. 2,831, 854 and the patent of E.U.A. No. 4,005,196, issued to Jandacek on January 25, 1977, incorporated herein by reference.
Liquid Oil The composition of the present invention includes a select liquid oil, as defined herein, which is used in combination with the liquid polyol fatty acid polyester described herein. The concentrations of the selected liquid oil are between 0.1% and 99.9%, preferably between 0.5% and 75%, most preferably between 1% and 50%, most preferably between 2% and 25% by weight of the composition. Liquid oils useful herein are those materials substantially free of liquid polyol fatty acid polyesters, isohexadecane, isopropyl palmitate, or mixtures of C13-C14 isoparaffins and polyacrylamide and laureth-7, and having a melting point of less of 30 ° C, preferably between -30 ° C and less than about 30 ° C, most preferably between -30 ° C and 27.5 ° C, and most preferably still between -30 ° C and 25 ° C. Suitable liquid oils include, but are not limited to, mineral oil, hydrocarbons having between 5 and 16 carbon atoms, esters of fatty alcohol with between 3 and 22 carbon atoms, fatty acid esters having between 3 and 30 carbon atoms, vegetable oils and mixtures thereof. Other liquid oils suitable for use herein are described in Patent No. WO 95-00166, issued to Gordon et al, on January 5, 1995, which is incorporated herein by reference. Mineral oil, also known as liquid petrolatum, is suitable for use in the present. It is a mixture of liquid hydrocarbons obtained from petroleum. See The Merck Index, tenth edition, annotation 7048, p. 1033 (1983), and International Cosmetic Ingredient Dictionary, fifth edition, vol. 1, pp. 415-417 (1993), which are incorporated herein by reference. Among the selected hydrocarbon liquid oils suitable for use herein are straight and branched chain hydrocarbons with between 5 and 16 carbon atoms. Among these hydrocarbon materials are, but not limited to, dodecane, sododecane, hydrogenated polyisobutylene and hexadecane. C5-C16 isoparaffins are also useful, excluding C3-C1 isoparaffins when these compounds are used in combination with polyacrylamide and laureth-7. C5-C6 isoparaffins are also known as C5-C16 branched hydrocarbons. Among the fatty alcohol esters suitable for use as a select liquid oil as defined herein are esters and diesters of fatty alcohols having between 3 and 22 carbon atoms. Also useful are fatty acid esters having between 3 and 28 carbon atoms. Among these ester materials are, but are not limited to, isopropyl myristate, isopropyl stearate, diisopropyl adipate and dioctyl sebacate (dioctyl ester of decanodioic acid). Other suitable liquid oils suitable for use herein are liquid vegetable oils at an ambient temperature between 20 ° C and 25 ° C. Among these convenient vegetable oils are cod liver oil, dolphin oil, lard oil, cow paw oil, porpoise oil, seal oil, sperm whale oil, whale oil, acorn oil, almond oil. , beech nut oil, chaulmugra oil, rape seed oil, soybean oil, sunflower seed oil, peanut oil, cottonseed oil, corn oil, safflower oil, olive oil, oil of sábalo, sesame seed oil, castor oil, hazelnut oil, hemp seed oil, flaxseed oil, black mustard seed oil, Mella Azadirachta oil, peanut oil, pistachio oil, seed oil of poppy, pumpkin seed oil, oil of Aleurítes Fordii, white mustard seed oil, pine oil, wheat germ oil and derivatives and mixtures thereof.
Topical vehicle The composition of the present invention includes between 0.1% and 99.9%, preferably between 50% and 99%, and most preferably between 60% and 95% by weight of a topical carrier for the combination of liquid polyol fatty acid polyester and of liquid oil, as well as for any other optional component of the present invention. The combination of liquid polyol fatty acid polyester and liquid oil of the present invention can be formulated in the form of a wide range of product types, including creams, lotions, milk, gel, hand and body lotions, skin creams , cleansing lotions that do not create foam, facial moisturizers, sunscreens, acne preparations, topical analgesics, mascara, lipstick, skin cleansers, hand cleansers, face and body, bath products, shampoos and the like. The vehicles and additional components required to formulate these products vary according to the type of product, and the person skilled in the art will be able to determine which components he will use. The topical vehicle can come in different forms. For example, as emulsion vehicles, including but not limited to emulsions of oil in water, water in oil, water in oil-oil in water, and oil in water-silicone. These emulsions can cover a wide range of viscosities, for example, between 100 cps and about 200,000 cps. Other suitable topical vehicles are anhydrous liquid solvents such as alcohols and silicones (e.g., ethanol, sodium propane, dimethicone, cyclomethicone and the like; aqueous single-phase liquid solvents (eg, hydroalcoholic solvent systems; and thickened versions) of these anhydrous and single-phase water-based solvents (for example, when the viscosity of the solvent has been increased to form a solid or semi-solid by the addition of the relevant gums, resins, waxes, polymers, salts and the like). of the topical carrier systems useful in the present invention are described in the following references, all incorporated herein by reference in their entirety: "Sun Products Formulary" Cosmetics &Toiletries, vol 105, pp. 122-139 (December 1990) "Sun Products Formulary", Cosmetics &Toiletries, vol 102, pp. 117-136 (March 1987), US Patent No. 4,960,764 issued Figueroa et al., October 2, 1990; patent of E.U.A. No. 4,254,105 issued to Fukuda et al., March 3, 1981; patent of E.U.A. No. 4,976,953 issued to Orr et al., December 11, 1990; patent of E.U.A. No. 5,073,372; issued to Tumer et al., December 17, 1991; patent of E.U.A. No. 5,585,104, issued to Ha et al., December 17, 1996; patent of E.U.A. No. 5,607,678 issued to Moore et al., March 4, 1997; the patent of E.U.A. No. 5,607,980, issued to McAtee et al., March 4, 1997; and the patent of E.U.A. No. 5,618,522, issued to Kaleta et al., April 8, 1997. The topical vehicle may also include an oil-in-water emulsion system with complex structures such as liquid crystals and crystalline gel networks. The nature of the liquid crystals, as well as the formation, characteristics and advantages thereof are described in greater detail in the following documents: G. Dahms, Properties of O / W Emulsions With Anisotropic Lameliar Phases, 101 Cosmetics & Toiletries, 113-115 (1986); P. Loll, Liquid Crystals, Cosmetic Emulsions, ICI Suriactants' Publication RP94-93E; and G.M. Eccleston, Multiple-Phase Oil-ln-Water Emulsions, 41, J. Soc. Cosmet. Chem., 1-22, (January / February 1990); all these documents are incorporated herein by reference.
Additional components It is possible to incorporate a large variety of additional components to the compositions herein. Of enunciative but not limitative way, between these components we have:
Pharmaceutical Active Compounds The compositions of the present invention may include a safe and effective amount of a pharmaceutical active compound. The phrase "safe and effective amount", as used herein, means an amount of an asset high enough to significantly or positively modify the condition to be treated, but low enough to avoid any serious side effects (at a reasonable benefit / risk ratio) , within the scope of a diagnosis or successful medical reasoning. The safe and effective amount of the pharmaceutical active will vary according to the specific active compound, the ability of the composition to penetrate the active through the skin, the amount of composition applied, the condition being treated in particular, the age and physical condition of the patient under treatment, the severity of the condition, the duration of the treatment, the nature of the concurrent therapies and similar factors. The pharmaceutical active compounds that can be used in the compositions of the present invention preferably constitute between 0.1% and 20% by weight of the compositions, most preferably between 0.1% and 10%, and most preferably still between 0.1% and 5%. . It is also possible to use mixtures of different pharmaceutical actives. Among the active pharmaceutical compounds that can be used are, but are not limited to: One of the active pharmaceutical compounds in the compositions of the present invention are the anti-acne drugs. These drugs include keratolytics such as salicylic acid, sulfur, lactic acid, glycolic acid, pyruvic acid, resorcinol and N-acetylcysteine.; retinoids such as retinoic acid and its derivatives (eg, cis and trans); antibiotics and antimicrobials such as benzoyl peroxide, octopirox, erythromycin, zinc, tetracycline, triclosan, azelaic acid and its derivatives, phenoxyethanol and phenoxypropanol, ethyl acetate, clindamycin and meclocycline; sebaptics such as flavonoids; alpha and beta hydroxy acids; and bile salts such as escimnol sulfate and its derivatives, deoxycholate and cholate. The preferred anti-acne actives are selected from the group consisting of salicylic acid, sulfur, resorcinol, lactic acid, zinc, erythromycin, benzoyl peroxide, and mixtures thereof. The most preferred is salicylic acid.
Among the active pharmaceutical compounds useful in the compositions of the present invention are non-steroidal anti-inflammatory drugs (NSAIDS). NSAIDs can be selected from the following categories: propionic acid derivatives; acetic acid derivatives; phenamic acid derivatives; diphenylcarboxylic acid derivatives; and oxicams. All of these NSAIDS are described in U.S. Pat. No. 4,985,459 issued to Sunshine at al., January 15, 1991, incorporated herein by reference. Most preferred are propionic NSAIDS including, but not limited to, aspirin, acetaminophen, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, microprofen, thioxaprofen , alminoprofen, thiaprofenic acid, fluprofen and bucloxic acid. Steroidal anti-inflammatory drugs including hydrocortisone and the like are also useful. Pharmaceutical active compounds useful in the compositions of the present invention include antipruritic drugs. Preferred antipruritic drugs to be included herein include pharmaceutically acceptable salts of metdilizine and trimeprazine. The pharmaceutical active compounds useful in the compositions of the present invention include anesthetic medicaments. Preferred anesthetic medicaments for inclusion herein include pharmaceutically acceptable salts of lidocaine, bupivacaine, chlorprocaine, digobucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxin and phenol. The active pharmaceutical compounds useful in the compositions of the present invention include antimicrobial drugs (antibacterial, antifungal, antiprotozoal and antiviral drugs). Preferred antimicrobial drugs to be included herein include pharmaceutically acceptable salts of β-lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, triclosan, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracycline, clindamycin, ethambutol, metronidazole, pentamidine, gentamicin, kanamycin, lineomycin, metacycline, methenamine, minocycline, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, miconazole and amanfadine. Preferred antimicrobial drugs to be included herein include tetracycline hydrochloride, erythromycin estolate, erythromycin stearate (salt), amikacin sulfate, doxycycline hydrochloride, capreomycin sulfate, chlorhexidine gluconate, chlorhexidine hydrochloride, chlortetracycline hydrochloride, hydrochloride of oxytetracycline, clindamycin hydrochloride, ethambutol hydrochloride, metronidazole hydrochloride, pentamidine hydrochloride, gentamicin sulfate, kanamycin sulfate, lineomycin hydrochloride, methacycline hydrochloride, methenamine hippurate, methenamine mandelate, minocycline hydrochloride, neomycin sulfate , netilmicin sulfate, paromomycin sulfate, streptomycin sulfate, tobramycin sulfate, miconazole hydrochloride, amanfadine hydrochloride, amanfadine sulfate, triclosan, octopirox, parachloromethaxyleneol, nystatin, tolnaftate and clotrimazole. Sunscreen agents are also useful herein. A wide variety of sunscreen agents are described in the patent E.U.A. No. 5,087,445 to Haffey et al., Issued February 1, 1992; patent of E.U.A. No. 5,073,372, Turner et al, issued December 17, 1991; patent of E.U.A. No. 5,073,371, Turner et al. issued on December 17, 1991; and Segarin, et al., in chapter VIII pages 189 et se. of Cosmetics Science and Technology, all of which is incorporated herein by reference in its entirety. Preferred among said sunscreens which are useful in the compositions of the present invention are those selected from the group consisting of 2-ethylhexyl p-methoxycinnamate, 2-ethylhexyl N, N-dimethyl-p-aminobenzoate, p-aminobenzoic acid, 2-phenylbenzimidazole-5-sulfonic acid, octocrylene, oxybenzone, homomenthyl salicylate, octyl salicylate, 4,4'-methoxy-t = butyldibenzoylmethane , 4-isopropyl dibenzoylmethane, 3-benzylidene camphor, 3- (4-methylbenzylidene) camphor, titanium dioxide, zinc oxide, silica, iron oxide, and mixtures thereof. Other useful sunscreens are those described in the U.S. patent. No. 4,937,370 of Sabatelli, issued June 26, 1990; and the patent E.U.A. No. 4,999,186 of Sabatelli et al., Issued March 12, 1991; These two references are incorporated by reference herein in their entirety. The sunscreen agents described therein have, in a single molecule, two distinct chromophore portions which have different absorption spectra of ultraviolet radiation. One of the chromophore portions absorbs predominantly in the UVB radiation range and the other absorbs strongly in the UVA radiation range. These sunscreen agents provide greater efficiency, wider UV light absorption, lower skin penetration and longer lasting efficacy compared to conventional sunscreens. Especially preferred examples of these sunscreens include those selected from the group consisting of 4-N, N- (2-ethylhexyl) methylaminobenzoic acid ester of 2,4-dihydroxybenzophenone, 4-N, N- (2-ethylhexyl) ester ) methylaminobenzoic acid with 4-hydroxydibenzoylmethane, 4-N, N- (2-ethylhexyl) methylaminobenzoic acid ester of 2-hydroxy-4- (2-hydroxyethoxy) benzophenone, 4-N, N- (2-ethylhexyl) ester 4- (2-hydroxyethoxy) dibenzoylmethane methylaminobenzoic acid, and mixtures thereof. In general, the compositions may comprise from about 0.5% to about 20% of the sunscreens useful herein. The exact amounts will vary depending on the chosen sunscreen and the desired Sun Protection Factor (SPF). SPF is a commonly used photoprotection measure of a sunscreen against erythema. See Federal Register. Vol. 43, No. 166, pp. 38206-38269, August 25, 1978, which is hereby incorporated by reference in its entirety. Also useful in the compositions of the present invention are sunless tanning agents including dihydroxyacetone, glyceraldehyde, indoles and their derivatives, and the like. These sunless tanning agents can also be used in combination with sunscreen agents. Other useful active compounds include skin whitening (or brightening) agents including, but not limited to, hydroquinone, ascorbic acid, kogic acid, and sodium metabisulfite.
Moisturizers and humectants The compositions of the present invention may also contain one or more additional moisturizing or humectant materials other than those described herein. A variety of these materials may be employed and each may be present at a level of from about 0.1% to about 20%, preferably from about 1% to about 10% and most preferably from about 2% to about 5%, by weight of the composition. These materials include guanidine; glycolic acid and glycolate salts (eg, ammonium and alkylammonium-quaternary); lactic acid and lactate salts (for example, ammonium and alkylammonium-quaternary); zabila in any of its variety of forms (for example, zabila gel); polyhydric alcohols such as sorbitol, glycerol, hexanetriol, propylene glycol, butylene glycol, hexylene glycol and the like; sugars and starches; sugar and starch derivatives (eg, alkoxylated glucose); hyaluronic acid; lactate monoethanolamine; acetamide monoethanolamine; and mixtures thereof.
Emulsifiers The compositions herein may contain various emulsifiers. These emulsifiers are useful for emulsifying the various carrier components of the compositions herein. Suitable emulsifiers can include any of a wide variety of nonionic, cationic, anionic, and zwitterionic emulsifiers which are described in the above patents and other references. See McCutcheon Detergents and Emulsifiers, US edition (1986), published by Allured Publishing Corporation; patent of E.U.A. No. 5,01 1, 681 of Ciotti et al., Issued April 30, 1991; patent of E.U.A. No. 4,421, 769 of Dixon et al, issued December 20, 1983; and patent of E.U.A. No. 3,755,560 of Dickert et al, issued August 28, 1973; These four references are incorporated herein by reference in their entirety. Suitable types of emulsifiers include glycerin esters, propylene glycol esters, polyethylene glycol fatty acid esters, polypropylene glycol grade acid esters, sorbitol esters, sorbitan anhydride esters, carboxylic acid copolymers, esters and glucose ethers, esters ethoxylates, ethoxylated alcohols, alkyl phosphates, polyoxyethylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps and mixtures thereof. Suitable emulsifiers may include, but are not limited to, polyethylene glycol sorbitan monolaurate 20 (Polysorbate 20), polyethylene glycol 5 soybean stearate, Steareth-20, Ceteareth-20, methylgluous ether distearate of PPG-2, Ceteth- 10, Polysorbate 80, cetylphosphate, potassium cetylphosphate, diethanolamine cetylphosphate, Polysorbate 60, glyceryl stearate, PEG-100 stearate and mixtures thereof. The emulsifiers can be used individually or as a mixture of two or more and can be included in concentrations ranging from about 0.1% to about 10%, preferably from about 1% to about 7%, and most preferably from about 1% to about 5%, by weight of the composition.
Carboxylic acid copolymer thickeners Another useful component in the compositions herein is a carboxylic acid copolymer thickener. These crosslinked polymers contain one or more monomers derived from acrylic acid, substituted acrylic acids, and salts and esters of these acrylic acids and substituted acrylic acids, wherein the crosslinking agent contains two or more carbon-carbon double bonds and is derived from a polyhydric alcohol. Preferred polymers for use herein are of two general types. The first type of polymer is an entangled homopolymer of an acrylic acid monomer or derivative thereof (eg, wherein the acrylic acid has substituents at the two carbon and three carbon positions independently selected from the group consisting of C1-alkyl 4, -CN, -COOH, and mixtures thereof). The second type of polymer is an entangled copolymer having a first monomer selected from the group consisting of an acrylic acid monomer or derivative thereof (as just described), a short chain alcohol acrylate ester monomer (s) say a C1-4) or derivative thereof (eg, wherein the acrylic acid portion of the ester has substituents at the two and three carbon positions independently selected from the group consisting of C1-4 alkyl, -CN, - COOH, and mixtures thereof), and mixtures thereof; and a second monomer which is a long-chain alcohol acrylate ester monomer (ie C8-0) or derivative thereof (eg, where the acrylic acid portion of the ester has substituents at the two and three carbon positions). independently selected from the group consisting of C -? - 4 alkyl, -CN, -COOH, and mixtures thereof). The combinations of these two types of polymers are also useful herein. In the first type of crosslinked homopolymers the monomers are preferably selected from the group consisting of acrylic acid, methacrylic acid, ethacrylic acid, and mixtures thereof, with acrylic acid being preferred. In the second type of crosslinked copolymers the acrylic acid monomer or derivative thereof is preferably selected from the group consisting of acrylic acid, methacrylic acid, ethacrylic acid, and mixtures thereof, with acrylic acid, methacrylic acid and mixtures of they are the preferred ones. The short chain alcohol acrylate ester monomer or derivative thereof is preferably selected from the group consisting of C1-4 alcohol acrylate esters, Cr4 alcohol alcohol methacrylate esters, alcohol ethacrylate esters of C1-4, and mixtures thereof, with the C1-4 alcohol acrylate esters, C1-4 alcohol methacrylate esters, and mixtures thereof, being preferred. The long chain alcohol acrylate ester monomer is selected from Cs-40 alkyl acrylate esters, with C10-30 alkyl acrylate esters being preferred. The crosslinking agent in both of these types of polymers is a polyether polyalkenyl of a polyhydric alcohol containing more than one alkenyl ether group per molecule, wherein the parent polyhydric alcohol contains at least 3 carbon atoms and at least 3 hydroxyl groups. Preferred crosslinkers are those selected from the group consisting of allyl esters of sucrose and allyl esters of pentaerythritol, and mixtures thereof. These polymers useful in the present invention are described in detail in the U.S.A. No. 5,087,445 to Haffey et al, issued February 1, 1992; U.S. Patent No. 4,509,949 to Huang et al, issued April 5, 1985; patent of E.U.A. No. 2,798,053 of Brown, issued July 2, 1957; which they incorporate here by reference. See also, CTFA International Cosmetic Ingredient Dictionarv (CTFA International Cosmetic Ingredient Dictionary), fourth edition 1991, pp. 12 and 80; which is also incorporated herein by reference. Examples of homopolymers of the first type useful herein commercially include carbomers, which are homopolymers of acrylic acid crosslinked with allylic esters of sucrose or pentaerythritol. The carbomers are available as the Carbopol® 900 series from B.F. Goodrich. Examples of copolymers of the second type useful herein commercially include copolymers of C?-3o alkyl acrylates with one or more monomers of acrylic acid, methacrylic acid, or one of their short chain esters (i.e. C1-4), wherein the interlacing agent is an allyl ester of sucrose or pentaerythritol. These copolymers are known as interlaced acrylates / polymers of C10-30 alkyl acrylate and are commercially available as Carbopol® 1342, Pemulen TR-1, and Pemulen TR-2, from B.F. Goodrich. In other words, examples of carboxylic acid polymer thickeners useful herein are those selected from the group consisting of C.sub.10-30 alkyl acrylate crosslinked carbomers, acrylates / polymers, and mixtures thereof. The compositions of the present invention may comprise from about 0.025% to about 1%, preferably from about 0.05% to about 0.75%, and most preferably from about 0.10% to about 0.50%, by weight of the carboxylic acid polymer thickeners.
Other additional components The compositions of the present invention may comprise a wide range of other additional components. The CTFA Cosmetic Ingredient Handbook, second edition, 1992, which is hereby incorporated by reference in its entirety, describes a wide variety of non-limiting cosmetic and pharmaceutical ingredients commonly used in the care industries of the body. hair and skin, which are suitable for use in the compositions of the present invention. Examples that are not limited to functional classes of ingredients are described on page 537 of this reference. Examples of these functional classes include: absorbers, abrasives, anti-acne agents, cake antiforming agents, foam anti-foaming agents, antimicrobial agents, antioxidants, binders, biological additives, pH-regulating agents, body-forming agents, chelating agents, additives chemicals, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, film formers, fragrance component, opacifying agents, pH adjusters, plasticizers, preservatives, propellants, reducing agents, additional skin conditioning agents, suspending agents (no surfactant), ultraviolet light absorbers, and viscosity increasing agents (aqueous and non-aqueous). Examples of other functional classes of materials useful herein that are well known to those skilled in the art include solubilizing agents, sequestering agents, and the like. Non-limiting examples of these additional components mentioned in the CTFA Cosmetic Ingredient Handbook, as well as other materials useful herein, include the following: vitamins and derivatives thereof [eg, vitamin C , Vitamin A (ie, retinoic acid), retinol, retinoids, and the like]; antioxidants; polyethylene glycols; polymers for assisting the film-forming properties and substantivity of the composition (such as a copolymer of eicosene and vinylpyrrolidone, an example of which is available from GAF Chemical Corporation as Ganex® V-220); preservatives to maintain the antimicrobial integrity of the compositions; antioxidants; chelators and sequestrants; interlaced and non-interlaced cationic polyacrylamides [eg, Saleare SC92 which has the designation CTFA polyquaternium 32 (and) mineral oil, and Saleare SC95 which has the designation CTFA polyquaternium 37 (and) mineral oil (y) PPG-1 trideceth -6]; and aesthetic components such as fragrances, pigments, dyes, essential oils, skin sensitizers, astringents, skin softening agents, skin healing agents and the like, non-limiting examples of these aesthetic components include clove oil, menthol , camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate, bisabolol, dipotassium glycyrrhizinate, and the like.
Methods of use The compositions of the present invention are used in conventional ways to provide cosmetic or pharmaceutical benefits appropriate to the product such as sun protection, anti-acne benefits, anti-wrinkle and anti-aging benefits of the skin, artificial tanning, analgesic benefits, conditioning benefits. of the skin, facial moisturization, protection for the lips, skin cleansing benefits, auxiliary for personal grooming, and the like. Said methods of use depend on the type of composition employed but generally involve topical application of an effective amount of the product to the hair or skin. By "effective amount" is meant an amount sufficient to provide the desired benefit. The typical amounts of the compositions of the present invention that are applied to the hair or skin will vary depending on the type of composition and the desired benefit, however, typical ranges are generally from about 1 gram to about 25 grams, with approximately 2 grams being typical .
EXAMPLES
The following examples describe and show better embodiments within the scope of the present invention. The examples are provided solely for the purpose of illustrating and should not be construed as limitations of the present invention, since many variations thereof are possible without departing from the spirit and scope of the invention. The ingredients are identified by the chemical or CTFA name.
EXAMPLE 1
A topical composition in the form of a bath product is prepared by combining the following ingredients using conventional mixing techniques. This composition utilizes a non-occlusive liquid polyol fatty acid polyester (liquid sucrose polyester) and a liquid oil to provide emolliency and aesthetic benefits without leaving the skin feeling harsh, sticky or oily.
Ingredients Percent by weight Alkyl ether glycerol sulfonate of C12 / 14 of 12.0 sodium Laureth-3 ammonium sulfate 3.00 Myristic acid 1.00 Myristic alcohol 1.00 Cocamidopropylbetaine 3.00 Polyester of liquid sucrose1 15.3 EDTA of tetrasodium 0.13 Glycerin 6.24 Perfume 0.80 Polyquat -10 (JR-30M) 0.30 Slip agent 0.20 Maleated soybean oil 1.00 Water CS 100
1 The liquid sucrose polyester is a mixture of esters of hexa-, hepta-, and octa-sucrose, predominantly the octa-ester esterified with mixed soybean oil fatty acids. In an appropriate container, Polyquat-10 is added to distilled water and allowed to mix until completely hydrated. The surfactants, and water soluble ingredients, are added and the mixture is heated by stirring at 70-80 ° C. In a separate container, the liquid sucrose polyester is combined with the liquid oil, heated by mixing until uniform, and then added to the heated mixture at 70-80 ° C. The mixture is allowed to cool to 25-35 ° C while continuing to stir. Then the ingredients of slippery agent and perfume are added with stirring, and the mixture is cooled to room temperature.
EXAMPLE 2
A topical composition in the form of a bath product is prepared by combining the following ingredients using conventional mixing techniques. This composition utilizes a blend of a non-occlusive liquid polyol fatty acid polyester (liquid sucrose polyester) and a liquid oil to provide emolliency and aesthetic benefits without leaving the skin feeling rough, sticky or oily.
Ingredients Percent by weight Ammonium lauryl sulfate 3.15 Laureth-3 ammonium sulfate 9.45 Lauroanfoacetate Na 5.40 Polyquatemium-10 0.30 Liquid sucrose polyester1 15.3 Mineral oil 3.00 Tetrasodium EDTA 0.13 Glycerin 3.00 Perfume 0.80 Citric acid 0.76 Lauryl alcohol 2.00 Water CS 100 1 The Liquid sucrose polyester is a mixture of esters of hexa-, hepta-, and octa-sucrose, predominantly the octa-ester esterified with mixed soybean oil fatty acids. In an appropriate container, Polyquatemium-10 is added to distilled water and allowed to mix until completely hydrated. The surfactants, and water soluble ingredients, are added and the mixture is heated by stirring at 70-80 ° C. In a separate container, the liquid sucrose polyester is combined with the liquid oil and lauryl alcohol, heated by mixing until uniform, and then added to the heated mixture at 70-80 ° C. The mixture is allowed to cool to 25-35 ° C while continuing to stir. The ingredients of slippery agent and perfume are then added by stirring, and the mixture is cooled to room temperature.
EXAMPLE 3
A topical composition in the form of a humectant is prepared by combining the following ingredients using conventional mixing techniques. This composition uses a mixture of a non-occlusive liquid polyol fatty acid polyester (liquid sucrose polyester) and a liquid oil to provide emolliency and aesthetic benefits without leaving the skin feeling rough, sticky or oily.
Ingredients Percentage by weight Cetyl alcohol 1.80 Stearic acid 0.25 Stearyl alcohol 1.20 Peg 100 stearate 0.25 Mineral oil 2.00 Liquid sucrose po1ester 4.00 Dimemetic 3502 0.50 Propylparaben 0.10 Arlatone (RMT) 21213 1.00 Glycerin 9.00 Urea 2.00 Octylmethoxycinnamate 2.00 Phenoxyethanol 0.25 Carbomer 13824 0.05 Carbomer 9545 0.35 Tetrasodium EDTA 0.10 Titanium dioxide 0.15 Methylparaben 0.20 NaOH 0.22 Dimethicone Q-214036 1.00 Water cs100
1 The liquid sucrose polyester is a mixture of esters of hexa-, hepta-, and octa-sucrose, predominantly the octa-ester esterified with mixed soybean oil fatty acids. 2 Fluid from Dow Corning® 200 (350 centistokes) from Dow Corning. 3 95% by weight of sorbitan stearate and 5% by weight of sucrose cocoate. 4 Carbopol® 1382 from B.F. Goodrich. 5 Carbopol® 954 from B.F. Goodrich. 6 Q-2 1403 Dow Corning® from Dow Corning which is a blend of 85% by weight dimethicone and 15% by weight dimethiconal.
A first premix of liquid sucrose polyester, Arlatone 2121 and other water soluble ingredients is prepared by mixing in water and heating. A second premix of oil phase ingredients other than silicones is prepared by mixing and heating and added to the aqueous premix. The resulting mixture is cooled. The silicones are then added to the resulting oil-in-water emulsion and the mixture is cooled before adding the minor ingredients.
Claims (19)
1. - A composition comprising: (a) of about
0. 1% to about 99.9% by weight of a liquid polyol fatty acid polyester having a melting point of about -30 ° C to about 30 ° C, further characterized in that the polyester of liquid polyol fatty acid has a polyol portion and at least 1 fatty acid portion, the polyol portion having at least 4 free hydroxyl groups wherein at least 60% of these free hydroxyl groups are esterified with one or more fatty acid moieties having from about 8 to about 22 carbon atoms; and (b) from about 0.1% to about 99.9% by weight of a liquid oil having a melting point of about -30 ° C to less than about 30 ° C, further characterized in that the liquid oil is substantially free of polyesters of fatty acid liquid polyols, isohexadecane, isopropyl palmitate, mixtures of C13-C14 isoparaffins and polyacrylamide and laureth-7, or combinations thereof. 2. The composition according to claim 1, further characterized in that the fatty acid portion contains from about 8 to about 18 carbon atoms.
3. - The composition according to claim 1, further characterized in that the polyol portion is selected from the group consisting of erythritol, xylitol, sorbitol, glucose, sucrose, and mixtures of the mims.
4. The composition according to claim 3, further characterized in that the polyol portion is sucrose.
5. The composition according to claim 4, further characterized in that the liquid polyol fatty acid polyester has a melting point of about -30 ° C to about 25 ° C.
6. The composition according to claim 1, further characterized in that the liquid oil has a melting point of about -30 ° C to about 25 ° C.
7. The composition according to claim 6, further characterized in that the liquid oil is selected from the group consisting of mineral oil, hydrocarbons having from about 5 to about 16 carbon atoms, fatty alcohol esters having from about 3. to about 22 carbon atoms, fatty acid esters having from about 3 to about 30 carbon atoms, vegetable oils, and mixtures thereof.
8. A topical composition comprising: (a) from about 0.1% to about 99.9% by weight of a liquid polyol fatty acid polyester having a melting point of about -30 ° C to about 30 ° C, further characterized because the. polyester of liquid polyol fatty acid has a polyol portion and at least 1 fatty acid portion, the polyol portion having at least 4 free hydroxyl groups wherein at least 60% of these free hydroxyl groups are esterified with one or more acid portions fatty acids having from about 8 to about 22 carbon atoms; (b) from about 0.1% to about 99.9% by weight of a liquid oil having a melting point of about -30 ° C to less than about 30 ° C, further characterized in that the liquid oil is substantially free of acid polyesters liquid polyol fatty acids, isohexadecane, isopropyl palmitate, mixtures of C13-C14 isoparaffins and polyacrylamide and laureth-7, or combinations thereof; and (c) from about 0.1% to about 99.9% by weight of a topical vehicle.
9. The composition according to claim 8, further characterized in that the fatty acid portion contains from about 8 to about 18 carbon atoms.
10. The composition according to claim 8, further characterized in that the polyol portion is selected from the group consisting of erythritol, xylitol, sorbitol, glucose, sucrose, and mixtures of the mims. 1.
The composition according to claim 10, further characterized in that the polyol portion is sucrose.
12. The composition according to claim 1, further characterized in that the liquid polyol fatty acid polyester has a melting point of about -30 ° C to about 25 ° C.
13. The composition according to claim 8, further characterized in that the liquid oil has a melting point of about -30 ° C to about 25 ° C.
14. The composition according to claim 13, further characterized in that the liquid oil is selected from the group consisting of mineral oil, hydrocarbons having from about 5 to about 16 carbon atoms, fatty alcohol esters having from about 3. to about 22 carbon atoms, fatty acid esters having from about 3 to about 30 carbon atoms, vegetable oils, and mixtures thereof.
15. The composition according to claim 8, further characterized in that the topical vehicle is an oil-in-water emulsion.
16. The composition according to claim 8, further characterized in that the topical vehicle is an anhydrous liquid solvent.
17. The composition according to claim 8, further characterized in that the composition is in the form of a hand lotion, body lotion, skin conditioning cream, skin protector, sunscreen, skin cream, composition against acne, skin regenerating product, non-foaming cleansing lotion, moisturizer, facial moisturizer, makeup, foundation, lipstick, lip balm, hand cleaner, face cleanser, body cleanser, bath product, shampoo , and mixtures thereof.
18. A method for treating hair or skin of humans comprising topically applying to a human in need of treatment a safe and effective amount of a composition in accordance with claim 1.
19. A method for treating hair or hair human skin comprising topically applying to a human in need of treatment a safe and effective amount of a composition according to claim 8.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/966,834 | 1997-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00004530A true MXPA00004530A (en) | 2001-07-09 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0794764B1 (en) | Topical skin care compositions containing thickened polyol carboxylic acid esters as skin conditioning agents | |
EP1032355A1 (en) | Compositions containing combinations of liquid polyol fatty acid polyesters and a liquid oil | |
KR19990035891A (en) | Compositions for topical application with improved skin feel | |
KR19990035892A (en) | Compositions for Topical Delivery of Active Ingredients | |
MXPA97003895A (en) | Topical compositions for care of the skin containing esters of carboxylic acid of poliol thickened as agents of conditioning of the p | |
US20010055599A1 (en) | Compositions containing select liquid polyol fatty acid polyesters | |
US20020039561A1 (en) | Topical skin care compositions containing thickened polyol carboxylic acid esters as skin conditioning agents | |
CA2095607C (en) | Leave-on facial emulsion compositions | |
US5731450A (en) | Oil adduct conditioners | |
AU7227598A (en) | Compositions containing select solid polyol fatty acid polyesters | |
WO1999024010A1 (en) | Compositions containing combinations of solid polyol fatty acid polyesters and a solid oil | |
EP0794765B1 (en) | Topical skin care compositions containing nonocclusive liquid polyol carboxylic acid esters as skin conditioning agents | |
MXPA00004530A (en) | Compositions containing combinations of liquid polyol fatty acid polyesters and a liquid oil | |
MXPA97003896A (en) | Topical compositions for care of the skin containing esters of carboxylic acid of non-oclusive liquid polyol as agents of conditioning of the p | |
MXPA99010832A (en) | Compositions containing select solid polyol fatty acid polyesters | |
MXPA99010840A (en) | Compositions containing select liquid polyol fatty acid polyesters | |
CZ410299A3 (en) | Mixtures containing combination of solid ester of polyhydroxylic fatty acid and liquid oil used for treating human hair and skin | |
DE10218181A1 (en) | Cosmetic or dermatological W/O emulsions especially for skin or cellulite treatment contain grapeseed oil and silicon emulsifier(s) | |
CZ410399A3 (en) | Preparations containing selected liquid polyhydroxyl polyesters of fatty acids |